New coagulant agent (ankaferd blood stopper) for open hemorrhages in hemophilia with inhibitor

Clinical and Applied Thrombosis/Hemostasis

Volumn 16, Issue 6, 2010, Pages 705-707

  Öner, Ahmet Faik ^a   Doǧan, Murat ^a   Kaya, Avni ^a   Sal, Ertan ^a   Bektaş, Mehmet Selçuk ^a   Yesilmen, Osman ^a   Ayhan, Harun ^a   Acikgoz, Mehmet ^a  

^a YYU Medicine Faculty   (Turkey)

Author keywords

Ankaferd blood stopper; hemophilia A; inhibitor

Indexed keywords

ANKAFERD BLOOD STOPPER; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; COAGULATING AGENT; CYCLOPHOSPHAMIDE; HEMOSTATIC AGENT; PLANT EXTRACT; PREDNISOLONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG;

ADOLESCENT; ANEMIA; ARTICLE; BLOOD CLOTTING TIME; BLOOD PRESSURE; BODY WEIGHT; CASE REPORT; CIRCUMCISION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE INCREASE; ERYTHROCYTE TRANSFUSION; FOLLOW UP; HEMOPHILIA A; HOSPITAL DISCHARGE; HUMAN; MALE; PARTIAL THROMBOPLASTIN TIME; PATIENT REFERRAL; PHYSICAL EXAMINATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; TREATMENT DURATION;

ADOLESCENT; HEMOPHILIA A; HEMORRHAGE; HEMOSTATICS; HUMANS; MALE; PLANT EXTRACTS;

EID: 77958449271     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029609337313     Document Type: Article

References (16)

1. Scott JP, Montgomery RR Hemorrhagic and thrombotic diseases. In: Kliegman RM, ed. Nelson Textbook of Pediatrics. 1 7 th ed. Philadelphia: WB Saunders Company ; 2007: 1504-1525.
2. Goker H., Haznedaroglu IC, Ercetin S., et al. Haemostatic actions of the folkloric medicinal plant extract Ankaferd blood stopper. J Int Med Res. 2008 ; 36 (1). 163-170.
3. Cipil H., Kosar A., Kaya A., et al. In vivo hemostatic effect of the medicinal plant extract Ankaferd blood stopper in rats pretreated with warfarin. Clin Appl Thromb Hemost. 2008. [Epub ahead of print].
4. Tasdelen Fisgin N., Tanriverdi Cayci Y., Coban AY, et al. Antimicrobial activity of plant extract Ankaferd blood stopper. Fitoterapia. 2009 ; 80 (1). 48-50.
5. Kurt M., Disibeyaz S., Akdogan M., Sasmaz N., Aksu S., Haznedaroglu IC Endoscopic application of Ankaferd blood stopper as a novel experimental treatment modality for upper gastrointestinal bleeding: a case report. Am J Gastroenterol. 2008 ; 103 (8). 2156-2158.
6. Ibis M., Kurt M., Onal IK, Haznedaroglu IC Successful management of bleeding due to solitary rectal ulcer via topical application of Ankaferd blood stopper. J Altern Complement Med. 2008 ; 14 (9). 1073-1074.
7. Kurt M., Kacar S., Onal IK, Akdogan M., Haznedaroglu IC Ankaferd blood stopper as an effective adjunctive hemostatic agent for the management of life-threatening arterial bleeding of the digestive tract. Endoscopy. 2008 ; 40 (suppl 2). 262.
8. Dogan OF, Ozyurda U., Uymaz OK, Ercetin S., Haznedaroglu IC New anticoagulant agent for CABG surgery. Eur J Clin Invest. 2008 ; 38 (5). 341.
9. Kurt M., Oztas E., Kuran S., Onal IK, Kekilli M., Haznedaroglu IC Tandem oral, rectal, and nasal administrations of Ankaferd blood stopper to control profuse bleedings leading to hemodynamic instability. Am J Emergency Med. ; IN PRESS.
10. Dargaud Y., Lambert T., Trossaert M. New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors. Haemophilia. 2008 ; 14 (suppl 4). 20-27.
11. Ghosh K., Shetty S., Jijina F., Mohanty D. Role of epsilon amino caproic acid in the management of haemophilic patients with inhibitors. Haemophilia. 2004 ; 10 (1). 58-62.
12. Robbins D., Kulkarni R., Gera R., Scott-Emuakpor AB, Bosma K., Penner JA Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy. Am J Hematol. 2001 ; 68 (3). 184-188.
13. Rech J., Hueber AJ, Leipe J., Manger B., Schett G., Kallert S. A case report of plasma exchange, steroids, mycophenolate mofetil and cyclophosphamide in acquired factor VIII inhibitors. Ther Apher Dial. 2008 ; 12 (5). 406-408.
14. Narukawa N., Abe T., Shouno M., et al. A case of factor VIII inhibitor-positive acquired hemophilia treated by plasmapheresis. Ther Apher. 1999 ; 3 (4). 323-325.
15. Wiestner A., Cho HJ, Asch AS, et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood. 2002 ; 100 (9). 3426-3428.
16. Sallah S., Wan JY Efficacy of 2-chlorodeoxyadenosine in refractory factor VIII inhibitors in persons without hemophilia. Blood. 2003 ; 101 (3). 943-945.